Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 15/20 | 0.87 |
| ▸ | SSTR1 | P30872 | 12/20 | 0.87 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26127350 | 0.93 | SSTR4 (1.00) | SSTR4SSTR1CHRM1CHRM3CHRM2 | |
| SCHEMBL30601806 | 0.93 | SSTR4 (1.00) | SSTR4SSTR1CHRM1CHRM3CHRM2 | |
| Trifluoroacetic Acid SCHEMBL30601817 | 0.90 | SSTR4 (0.69) | SSTR4SSTR1CHRM1 | |
| Trifluoroacetic Acid SCHEMBL30601840 | 0.85 | SSTR4 (0.62) | SSTR4SSTR1CHRM1 | |
| SCHEMBL30601834 | 0.84 | SSTR4 (0.78) | SSTR4SSTR1CHRM1CHRM3 | |
| SCHEMBL26123784 | 0.84 | SSTR4 (0.78) | SSTR4SSTR1CHRM1CHRM3 | |
| SCHEMBL26127751 | 0.82 | SSTR4 (0.78) | SSTR4SSTR1 | |
| Trifluoroacetic Acid SCHEMBL30601820 | 0.80 | SSTR4 (0.56) | SSTR4SSTR1 | |
| Trifluoroacetic Acid SCHEMBL30601829 | 0.79 | SSTR4 (0.64) | SSTR4SSTR1CHRM1 | |
| SCHEMBL26122040 | 0.78 | SSTR4 (0.69) | SSTR4SSTR1CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250188037-A1 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | TAKEDA PHARMACEUTICALS CO (JP) | 2025-06-12 | — | — | US | disclosed |
| CN-119585238-A | N- (pyrrolidin-3-yl or piperidin-4-yl) acetamide derivatives | 武田药品工业株式会社 | 2025-03-07 | — | — | CN | disclosed |
| EP-4499224-A1 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2025-02-05 | — | — | EP | disclosed |
| WO-2023187677-A1 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-10-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188037-A1 | N-(PYRROLIDIN-3-YL OR PIPERIDIN-4-YL)ACETAMIDE DERIVATIVES | SSTR4, SSTR3, SSTR1 | SSTR4 1/4885SSTR1 3/4885CHRM1 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.